REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 Apr 2024 14:34:07 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 Apr 2024 10:36:55 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

04 Apr 2024 15:05:04 By Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 Mar 2024 15:05:40 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 Feb 2024 15:05:50 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 Feb 2024 15:05:47 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

01 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 06:00:08 By Nasdaq GlobeNewswire

Revolution Medicines Completes Acquisition of EQRx

09 Nov 2023 08:10:58 By Nasdaq GlobeNewswire

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

08 Nov 2023 10:30:46 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

06 Nov 2023 15:05:18 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

01 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

31 Oct 2023 15:15:00 By Nasdaq GlobeNewswire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

22 Oct 2023 01:30:28 By Nasdaq GlobeNewswire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

13 Oct 2023 10:50:29 By Nasdaq GlobeNewswire

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

04 Oct 2023 15:05:07 By Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

19 Sep 2023 06:00:38 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

17 Aug 2023 15:05:58 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

08 Aug 2023 15:05:04 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

03 Aug 2023 15:05:54 By Nasdaq GlobeNewswire